Population Pharmacokinetics of Tigecycline for Critically Ill Patients Undergoing Continuous Renal Replacement Therapy
Shuping Song,Jieqiong Liu,Wei Su,Haitao Yu,Binbin Feng,Yinshan Wu,Feng Guo,Zhenwei Yu
DOI: https://doi.org/10.2147/dddt.s473080
IF: 4.3188
2024-10-05
Drug Design Development and Therapy
Abstract:Shuping Song, 1, &ast Jieqiong Liu, 2, 3, &ast Wei Su, 1 Haitao Yu, 4 Binbin Feng, 1 Yinshan Wu, 1 Feng Guo, 1 Zhenwei Yu 2 1 Intensive Care Unit, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 2 Department of Pharmacy, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China; 3 Department of Pharmacy, The 903rd Hospital of PLA Joint Logistic Support Force, Hangzhou, People's Republic of China; 4 Department of Clinical Laboratory, Sir Run Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, People's Republic of China &astThese authors contributed equally to this work Correspondence: Feng Guo; Zhenwei Yu, Email ; Background: Tigecycline is considered one of the last resorts for treating infections caused by multidrug-resistant bacteria. Continuous renal replacement therapy (CRRT) is widely used in critically ill patients, especially those with acute kidney injury or severe infections. However, pharmacokinetic data for tigecycline in patients receiving CRRT are limited. Methods: This was a single-center prospective clinical study with intensive sampling that included critically ill patients who received tigecycline and CRRT. A population pharmacokinetic (PPK) model was developed and evaluated by goodness-of-fit plots, bootstrap analysis, visual predictive checks, and numerical predictive checks. Pharmacokinetic/pharmacodynamic target attainment and cumulative fraction of response analyses were performed to explore the potential need for dose adjustments of tigecycline in CRRT. Results: In total, 21 patients with 167 concentrations were included. A two-compartment model adequately described the tigecycline concentration–time points, but no covariates were found to adequately explain the viability in the pharmacokinetic parameters of tigecycline. The typical values of CL, Q, V1 and V2 were 4.42 L/h, 34.8 L/h, 30.9 L and 98.7 L, respectively. For most infections, the standard regimen of 50 mg/12 h was deemed appropriate, expect for skin and soft skin tissue infections and community-acquired pneumonia caused by Acinetobacter baumannii and Klebsiella pneumoniae , which required a dosage regimen of 100 mg/12 h or higher. Conclusion: A tigecycline PPK model describing critically ill patients undergoing CRRT was successfully developed. The optimized dosage regimens for various infections are recommended. Keywords: tigecycline, population pharmacokinetics, critically ill, continuous renal replacement therapy Tigecycline is a glycylcycline antimicrobial drug that is approved by the FDA for treating complicated intra-abdominal infections (cIAIs), skin and soft skin tissue infections (cSSSIs) and community-acquired pneumonia (CAP). 1,2 Tigecycline exhibits broad-spectrum antimicrobial activity and demonstrates potent in vitro efficacy against multidrug-resistant (MDR) bacteria, including extended-spectrum β-lactamase (ESBL)-producing Enterobacteriaceae, methicillin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococci, and multidrug-resistant Acinetobacter baumannii . 1 Thus, tigecycline is an alternative agent for difficult-to-treat infections in intensive care units (ICUs), especially for MDR bacterial infections that resistant to other antibiotics. 3 Continuous renal replacement therapy (CRRT), as one of the three supportive techniques in critical care, is extensively utilized for the management of critically ill patients, especially those with severe acute kidney injury (AKI), hemodynamic instability or the need to remove inflammatory mediators. 4,5 The use of CRRT may lead to increased antibiotic clearance and reduced exposure. 6–8 Accordingly, a higher antibiotic dosage may be necessary in patients during CRRT. 9 Although several small-sample studies have indicated that dose adjustment of tigecycline seems unnecessary during CRRT, there are still experts who believe that it is too early to draw this conclusion. 10–13 Hence, in this prospective study, we aimed to develop a PPK model of tigecycline in critically ill patients undergoing CRRT, identify the factors influencing its pharmacokinetics, and utilize the final model to optimized tigecycline dosage regimens for different bacterial infections. The detailed study protocol was published in our previous study, which complied with the Declaration of Helsinki. 14 Briefly, we included critically ill patients who were treated with intermittent intravenous tigecyc -Abstract Truncated-
pharmacology & pharmacy,chemistry, medicinal